Difference between revisions of "Blastic plasmacytoid dendritic cell neoplasm"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) |
||
Line 20: | Line 20: | ||
|} | |} | ||
===Regimen {{#subobject:8044|Variant=1}}=== | ===Regimen {{#subobject:8044|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 50%; text-align:center;" |
− | !style="width: | + | !style="width: 25%"|Study |
− | !style="width: | + | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[http://www.bloodjournal.org/content/124/3/385.long Frankel et al. 2014] | |[http://www.bloodjournal.org/content/124/3/385.long Frankel et al. 2014] |
Revision as of 01:10, 10 May 2019
Section editor | |
---|---|
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO ![]() |
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tagraxofusp monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Frankel et al. 2014 | Phase I/II, <20 pts |
Chemotherapy
- Tagraxofusp (Elzonris) 12 mcg/kg IV over 15 minutes once per day on days 1 to 5
21-day cycles
References
- Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. Epub 2014 May 23. link to original article PubMed